• Regenacy Pharmaceuticals

  Participated · Series A · Mar 2020

  Regenacy Pharmaceuticals is developing ricolinostat, an oral selective histone deacetylase 6 (HDAC6) inhibitor intended to reverse peripheral nerve dysfunction and relieve pain, numbness, and motor deficits in diabetic and other peripheral neuropathies. Preclinical models have shown efficacy of ricolinostat and other HDAC6 inhibitors in diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN), and Charcot‑Marie‑Tooth disease, with a promising safety and tolerability profile. The company recently completed enrollment in a double-blinded, placebo-controlled Phase 2 study of ricolinostat in painful DPN, with initial results expected later this year. Regenacy said it will advance a joint venture, Beijing 3E‑Regenacy Pharmaceuticals Co., Ltd., to investigate ricolinostat in CIPN patients in China. The company also maintains a portfolio of selective HDAC1/2 inhibitors with potential applications in blood diseases and neurological disorders. Regenacy plans to use proceeds from its Series B financing to continue advancing the ricolinostat clinical development program. Regenacy Pharmaceuticals is a clinical-stage biopharma focused on developing selective HDAC6 inhibitors, principally ricolinostat, to restore nerve function in diabetic and other peripheral neuropathies. Ricolinostat is an oral, selective HDAC6 inhibitor with prior Phase 1 and 2 data showing an excellent safety and tolerability profile and preclinical evidence of restoring nerve fibers and reversing pain and numbness. The company also holds a portfolio of selective HDAC1 and HDAC2 inhibitors targeting major blood diseases and neurological indications. Regenacy plans to advance ricolinostat into a Phase 2 proof-of-concept trial in diabetic peripheral neuropathy and will evaluate the candidate in chemotherapy-induced peripheral neuropathy and CMT Type 2. The company intends to use the proceeds from its recent financing to initiate the Phase 2 study. Regenacy is based in Waltham, Massachusetts.

• Arbe

  Participated · Equity · Jul 2018

  Arbe develops a high-resolution 4D imaging radar chipset designed to detect, separate, identify and track hundreds of objects with high horizontal and vertical resolution and long range. The company says its chipset generates images 100 times more detailed than other solutions and can simultaneously localize and map the environment while mitigating mutual radar interference and reducing false alarms. Arbe plans to use new funding to hire more employees and to bring its radar systems into full production for Tier 1 suppliers. CEO Kobi Marenko said the company aims to enable Tier 1 automakers and OEMs to replace legacy chipsets and meet NCAP and ADAS safety requirements. Arbe already counts five Tier 1 customers — two in China and three in Europe — though it did not name the suppliers. The company also claims its radar can enable SAE Level 3 automation in passenger vehicles without requiring lidar. Arbe Robotics designs an ultra high-resolution 4D imaging radar that enables vehicles to sense the environment in any weather and lighting across long, mid and short ranges. Its radar, based on proprietary chipsets, detects cars, motorcycles, bikes and humans and is positioned as a next-generation safety product for ADAS and autonomous driving. The company intends to use the new funding to expedite product development for the autonomous-vehicle market and to expand its customer-facing operations in the U.S. and China. Arbe maintains business development and customer service locations in China and the United States. Founded in 2015 by CEO Kobi Marenko, the company is advancing its imaging radar technology toward commercial automotive applications. The product roadmap and go-to-market efforts are focused on integrating the radar into vehicle platforms and scaling customer deployments. Arbe develops an ultra-high-resolution radar and SLAM-based 4D imaging system aimed at automotive applications to detect and identify objects regardless of exterior conditions. The product combines an ultra high-resolution radar and Simultaneous Localization and Mapping (SLAM) algorithms to improve target separation, enhance resolution, remove false alarms, and distinguish objects with roughly one-degree resolution. The company pivoted from a prior drone focus to prioritize road vehicles and has demonstrated its system to customers, showing the ability to differentiate people, trees, and motorcycles. Arbe plans five in-car trials in the U.S. with large partners within the next year or two and is in final stages of securing a manufacturing partner to mass-produce its chips. The recent financing is intended to finish the product, support additional tests, and establish a U.S. support center; the company describes itself as capital efficient. To date Arbe has raised $12M and says it is prepared to raise more when commercial deals beyond trials materialize, aiming for a higher valuation.

• iStaging

  Participated · Series A · Sep 2016

  iStaging Corp. is a Taipei, Taiwan–based provider of augmented and virtual reality technology led by CEO and founder Johnny Lee. The company offers AR and VR products including platform-centric apps for mobile devices and VR glasses for visualization. Its tools enable businesses, notably furniture makers and real estate agents, to let clients visualize end-products in realistic settings. iStaging secured US$5m in pre-Series A funding to support expansion. The company intends to use the funds to grow into territories where it already has satellite sales offices: Redwood City, California; Paris, France; and China.

• ASLAN Pharmaceuticals

  Participated · Equity · Jul 2016

  ASLAN Pharmaceuticals is a biopharmaceutical company developing ASLAN003 for autoimmune gastrointestinal and skin diseases and certain skin conditions. The company has closed a secured loan facility with K2 HealthVentures providing up to $45 million of secured debt financing. The facility includes a $20 million initial term loan funded at closing and a further $25 million subject to certain terms and conditions. ASLAN intends to use the proceeds to advance the clinical development of ASLAN003 and for general corporate purposes. The company expects to initiate a Phase 2 clinical trial of ASLAN003 in inflammatory bowel disease in early 2022. The loan provides near-term funding to support those planned clinical activities. ASLAN Pharmaceuticals is a biotech focused on developing immunotherapies and targeted agents for tumour types highly prevalent in Asia. Its pipeline comprises four novel therapeutic agents, with lead drug varlitinib currently in phase 2 trials for cholangiocarcinoma, gastric cancer and breast cancer. Proceeds from the new financing will be used to support clinical development of the pipeline. The company said the financing bolsters its financial position and will accelerate progress across its clinical programme. ASLAN has raised over US$100 million to date, including a US$43 million Series C in December 2015 led by Accuron (a Temasek subsidiary). The announcement was released from Singapore and the company is pursuing growth in Taiwan and the region. Aslan Pharmaceuticals is a Singapore-based biotech focused on developing immunotherapies and targeted agents for tumor types prevalent in Asia. The company maintains a proprietary pipeline of four development-stage candidates addressing multiple indications including gastric and breast cancers and inflammatory diseases. Its most advanced programs are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer and trials in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint target, and cMET. Aslan also operates a global medical device and diagnostics division, Accuron MedTech, led by Abel Ang. The company is led by CEO Dr. Carl Firth and plans to use recent proceeds to accelerate clinical development of ASLAN001, which received Orphan Drug Designation in cholangiocarcinoma from the US FDA.

No current team members are available.